We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

AACC Launches COVID-19 Immunity Study at 2021 Annual Scientific Meeting and Clinical Lab Expo

By LabMedica International staff writers
Posted on 31 Aug 2021
Print article
Illustration
Illustration
The American Association for Clinical Chemistry (AACC; Washington, DC, USA) is launching the COVID-19 Immunity Study, which will examine immune responses to SARS-CoV-2 vaccination or prior infection in a diverse group of volunteers.

Despite continued efforts by the scientific community to understand all aspects of COVID-19, it is still not known how long the currently available SARS-CoV-2 vaccines can provide protection against the SARS-CoV-2 virus. In order to gain further insights into this issue, AACC’s study will also further examine the utility of serologic tests as a means to measure lasting immunity.

AACC will collect blood samples for the planned study from attendees and exhibitors at the 2021 AACC Annual Scientific Meeting & Clinical Lab Expo to be held in Atlanta on September 28-30. All study participants must be 18 years of age and efforts will be made to ensure that the research cohort is as diverse as possible. This approach to sample collection is modeled after AACC’s Universal Sample Bank program, which used samples from attendees of the 2015 AACC Annual Scientific Meeting in support of important research related to troponin. People who are unable to attend the meeting in person can also contribute to the study by submitting answers to a 10-minute COVID-19 health questionnaire. In return for donating blood, the study participants will receive the results of their individual antibody profile tests after all the collected samples have been analyzed.

Related Links:
American Association for Clinical Chemistry

Gold Member
Veterinary Hematology Analyzer
Exigo H400
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Malondialdehyde HPLC Test
Malondialdehyde in Serum/Plasma – HPLC
New
Benchtop Cooler
PCR-Cooler & PCR-Rack

Print article
ADLM

Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.